Post Profile






Nivolumab plus ipilimumab in melanoma: Added benefit in certain patients

(Institute for Quality and Efficiency in Health Care) Treatment-naive patients with BRAF V600 mutation-negative tumor survive longer. This advantage depends on sex, however. And severe side effects are more common.
read more

share

Related Posts


Cobimetinib in melanoma with BRAF V600 mutation: Indication of minor added benefit

Academics / General Science : Science Codex

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. The Federal Joi...

Cobimetinib in advanced melanoma with BRAF V600 mutation: Added benefit now considerable

Academics / General Science : Science Codex

Cobimetinib (trade name: Cotellic) has been approved since November 2015 in combination with vemurafenib for the treatment of adults with advanced, i.e. metastatic or unresectable, melanoma with a BRAF V600 mutation. In a dossier as...

Ipilimumab in advanced melanoma: added benefit for non-pretreated patients not proven

Academics / General Science : Science Codex

In early 2014, the German Institute for Quality and Efficiency in Health Care (IQWiG) assessed the added benefit of ipilimumab in non-pretreated patients with advanced melanoma. The drug manufacturer claimed a noticeable increase in...

Talimogene laherparepvec in melanoma: Added benefit not proven

Health : EurekAlert: Health

(Institute for Quality and Efficiency in Health Care) The data from the only study cited by the drug manufacturer in its dossier were unsuitable for the assessment.

Ipilimumab in advanced melanoma: Added benefit for non-pretreated patients not proven

Academics / General Science : Science Codex

The German Institute for Quality and Efficiency in Health Care (IQWiG) already assessed the added benefit of ipilimumab in advanced melanoma in 2012. A considerable added benefit was found for patients who had already received previ...

Comments


Copyright © 2016 Regator, LLC